CRISPR-GPT — The Future of Bioengineering
Merging CRISPR Gene Editing with Agentic AI A new AI co-pilot automates genome engineering, accelerating discovery and democratizing CRISPR expertise. Introduction: The Convergence…
A Year Since BIO
One Year On: The Future of CRISPR is Now As I prepare for my second BIO-International Convention as CEO of ERS Genomics, I’ve taken a…
CVC successfully appeals prior CRISPR U.S. patent decision
U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute with the Broad Institute. Decision…
AI + CRISPR: Powering the 21st Century’s Biological Revolution
We stand at the forefront of a pivotal moment in human innovation—where AI and CRISPR gene editing converge to power what can only be described…
Licensee Case Study: Bioneer
Making CRISPR more accessible for scientific innovation At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the foundational IP co-owned by Professor…
ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement
License agreement provides Jumpcode Genomics access to CRISPR gene editing technology to enhance next-generation sequencing capabilities Dublin, Ireland, and San Diego, CA, 27 March,…
European Patent Office Grants CVC Portfolio Key CRISPR Patent
European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent…
Annual Letter From The CEO
Dear Stakeholders, As we step into 2025, I’d like to take a moment to reflect on the remarkable progress we’ve made in the CRISPR landscape…
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
The new Express License service removes barriers to accessing this transformative gene editing technology for startups. An Express License provides fast, simple and affordable…